XCellCure is a startup biotechnology company focused on transforming modern cardiac care. We are excited to launch our first product the AMiAware, currently available as an investigational use only device to aid in the prevention of recurrent heart attack through patient-centered risk stratification utilizing 13 novel biomarkers. The motif of our clinical approach is to noninvasively diagnose and prognosticate patients experiencing acute coronary symptoms in order to assist in patient monitoring, aid therapeutic selection, prevent fatality, and reduce morbidity of cardiovascular disease. We will be releasing a collection of cardiac devices for the research, clinical and point of care realms to supplement and improve current care and patient quality of life. XCellCure’s novel multimarker cardiac panel has application for emergency room personnel to quickly assess the probability of an impending heart attack. Our first product, the AMiAware, allows users insight to key clinical evidence through a unique “Signature of Disease” that guides physicians to make accurate and swift decisions, resulting in higher quality of care for patients with acute coronary syndromes. The AMiAware brings results for 13 known cardiac biomarkers into the diagnostic arsenal of cardiologists in a user-friendly platform giving doctors the decisive power to administer patient-centered therapy more rapidly than ever before. Our aim is to revolutionize cardiac diagnostics through an emphasis on prognostics and prevention. The XCellCure AMiAware will give doctors the foresight to predict and stop a heart attack before it has even started. By focusing on preventative medicine with a prognostic “Signature of Disease” approach, the AMiAware’s multiplexed proteomic biomarker panel can prevent patients from getting to the point at which precious heart tissue is already dying, saving hundreds of thousands of U.S. lives and millions of dollars each year.